Globe Life Inc. Third Quarter Earnings - GLOBE LIFE INC

Explicit Guidance:

• 2026 Net Operating EPS: $15.35 – $15.65 (midpoint down from prior guidance).
• 2026 Net Operating Income Growth: Not explicitly quantified as a percentage, but implied by EPS guidance and share count dynamics.
• 2026 Adjusted Life Underwriting Margin: 44% – 45% of premium (excluding assumption update impacts).
• 2026 Health Underwriting Margin: 4% – 4.5% growth in dollars; 20% – 22% of premium in Q4 2026.
• 2026 Administrative Expenses: ~7.3% of premium (flat vs. 2025); expected to be flat or slightly lower in 2027.
• 2027 Net Operating EPS: $16.10 – $17.10 (7% growth at midpoint).
• 2027 Total Premium Revenue Growth: 6% – 8%.
• 2027 Life Premium Revenue Growth: 2% – 4%.
• 2027 Health Premium Revenue Growth: 13% – 15%.
• 2027 Underwriting Margins: Life 42% – 45%; Health 20% – 24%.
• 2027 Health Underwriting Margin Dollars: 7% – 9% growth.
• 2027 Net Operating Income Growth: 1% – 2% (excluding buyback impact).
• 2027 Net Investment Income (NII) Growth: 2.5% – 3.5%.
• 2027 Required Interest Growth: 3.0% – 4.0%.
• 2027 Excess Investment Income Growth: Flat to slightly declining.
• 2027 Parent Excess Cash Flow: $850 million – $950 million.
• 2027 Shareholder Returns: Dividends + Share Repurchases projected to be 70% – 75% of Net Operating Income (midpoint).
• 2026 Share Repurchases: $725 million – $775 million midpoint ($65M increase from prior guidance).
• 2026 Dividends: ~$95 million total.
• 2027 Dividend from Bermuda: Expected ~$150 million (subject to regulator approval; estimated to flow to parent in late 2027).
• Investment Portfolio Yield (2026): Total long-term assets ~5.51%; Fixed maturities ~5.33%.
• Investment Portfolio Yield (2027): Total long-term assets 5.50% – 5.55%; Fixed maturities ~5.35%.
• 2026 Fixed Maturity Investment Volume: Midpoint assumption of $175M – $200M at 6.4% – 6.5% yield.
• 2026 Total Investment Volume (incl. CMBS/Non-fixed): $250M – $300M at 6.75% – 7% yield.

Business-Segment Outlook:

• American Income Life (AIL):
  • 2027 Net Life Sales Growth: Mid-to-high single-digit.
  • 2026 Average Producing Agent Count: Decrease of ~5%.
  • 2026 Net Life Sales: Flat.
  • Strategy: Structural compensation changes rolling out late 2026 expected to drive growth/recruiting in early 2027.
• Liberty National:
  • 2027 Net Life Sales Growth: Low double-digits.
  • 2026 Average Producing Agent Count: Increase of ~9%.
  • 2026 Net Life Sales: Increase of ~10%.
  • 2026 Net Health Sales: Decrease of ~7%.
  • 2027 Net Health Sales Growth: Low double-digits.
  • Strategy: Shift in sales presentation to emphasize health products.
• Family Heritage:
  • 2026 Average Producing Agent Count: Decrease of ~5%.
  • 2027 Net Health Sales Growth: Low double-digits.
  • 2026 Net Health Sales Growth: ~10%.
  • Outlook: Optimistic on long-term growth driven by improved retention and middle management growth.
• Direct-to-Consumer (DTC):
  • 2026 Net Life Sales: Decrease of ~9%.
  • 2027 Net Life Sales Growth: Low single-digits.
  • Lead Generation: Anticipate ~1 million agency leads this year.
  • Strategy: Adapting to AI-powered search and digital advertising shifts; expecting "encouraging improvement" in inquiry rates in H2 2026.
• United American Group Agency (UAGA):
  • 2026 Net Health Sales Growth: ~45%.
  • 2027 Net Health Sales Growth: High single-digit.
  • 2026 Health Underwriting Margin: Negative due to high-severity claims at "Every" and CMS processing delays; normalized margin expected ~7% excluding these items.
  • Every Business: Startup stage; currently negative margin; expects volatility to stabilize as volume grows to scale (~$100M annualized premium by 2027, ~50 groups); pricing adjustments made for renewals.
  • MedSupp: Rate increases effective Q2 2027 to address CMS-driven claim trend inflation.

Market and Competitive Outlook:

• Medicare Supplement (MedSupp): Tailwinds from high volume of 65+ entrants and migration from Medicare Advantage to Supplement; rate increases implemented Q2 2026.
• Digital Marketing: Structural shift in AI-powered search impacting DTC channels; competitors facing similar headwinds; Globe Life adapting content for AI visibility.
• Agent Market: Economic environment viewed as enhancing value proposition for "own your own business" opportunity; recruiting pipeline remains strong.
• Health Segment Volatility: Recognized volatility in startup health block (Every) due to high-severity claims; market sees "reshuffling" of groups; disciplined underwriting rejecting 70%+ of new cases.

Macro / Industry Outlook:

• Interest Rates: Short-term rate changes expected to have "no meaningful impact" on net income due to floating-rate liability matching.
• Investment Philosophy: Focus on long-duration assets to match liabilities; low exposure to non-investment grade (BBB: 39% of fixed maturities; below BBB: 2.9%).
• Claims Trends: Expect CMS processing delays to normalize; high-severity claim trends at "Every" expected to persist but diminish as percentage of book with scale; inflation from past CMS issues to be reflected in 2027 rate filings.
• Regulation: Reciprocal jurisdiction approvals received allowing dividend flows from Bermuda; ongoing rate filings for MedSupp.
• Economic Environment: Believed to be favorable for agency recruitment; agents viewed as offering financial security during uncertain economic times.

Strategic Initiatives:

• Bermuda Operations:
  • Completed new reinsurance session reinsuring portion of AIL new business and enforced policies to Globe Life REIT (Q3 2026).
  • Targeting ~25% of statutory reserves reinsured long-term.
  • Aiming to increase parent excess cash flow run rate from historical $600–700M to $850–950M by 2027.
• Capital Management:
  • Share repurchases remain primary use of excess cash after dividends.
  • Target consolidated RBC ratio: 300% – 320% (US subsidiaries).
• Technology & AI:
  • Rolling out AI-enabled advertising for DTC.
  • Expanding AI use across company to contain expense growth below revenue growth; admin expense ratio to be flat or lower in 2027.
• Compensation Restructuring:
  • Additional structural compensation changes for AIL agents rolling out late 2026 to focus on recruiting/training incentives.
• Pricing Actions:
  • Implementing price adjustments on United American health business upon renewal and for new business to improve margins.

Risks and Headwinds to Outlook:

• Claim Volatility: High-severity claims at "Every" and CMS processing delays (remnants in Q4) creating margin uncertainty; loss ratios expected to be higher than target for remainder of 2026.
• Regulatory Risk: Bermuda dividend distributions subject to regulator approval; rate filing approvals for 2027.
• Margin Dilution: Health underwriting margin percentage expected to decline in 2026 due to business mix and volatility; 2027 margin range (20-24%) is wider than prior to account for volatility.
• Investment Income: Excess investment income growth may decline in 2027 due to reduced invested asset base (capital returning to parent/shareholders) while required interest remains stable.
• Digital Transition: Continued disruption in digital search algorithms could delay DTC sales recovery.

Management Tone on the Future:

• Confidence: Generally optimistic regarding long-term growth, particularly in life sales and agent recruiting.
• Hedges: Explicitly notes volatility in the health segment ("Every") and the non-guaranteed nature of assumption update gains.
• 2027 Outlook: Management acknowledges 2027 is a transition year with lower EPS growth (1-2% organic) driven by capital efficiency and investment income dynamics, but expects 7% total EPS growth driven by buybacks.
• Trend: Believes assumption update gains in 2027 will be "lower in magnitude" than 2026; expects 2027 to be the starting point for "solid credibility" in the Every health block.

Miscellaneous:

• Q3 2026 Actuals: Net income $361M ($4.62/share); Net operating income $379M ($4.84/share).
• Assumption Updates: Q3 remeasurement gain of $120M (Life: $96M; Health: $24M); actual claims experience favorable relative to long-term assumptions.
• Investment Activity: Q3 invested $833M in fixed maturities at 6.4% yield; $94M in commercial mortgages.
• Share Repurchases: Q3 repurchased 1.1M shares ($185M total cost).